This is a working overview of MOD GRF(1-29), written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-04-14. Anything still debated is marked as such rather than presented as settled.
Peptide degradation proceeds mainly through hydrolysis, oxidation of methionine, and deamidation of asparagine or glutamine residues. The maleimide group on the albumin-binding variant can also react with thiols or hydrolyze in aqueous media. Because these pathways accelerate with temperature and pH extremes, handling conditions strongly influence measured stability. Stability data in the public literature are limited and often generated under differing conditions, so general statements about shelf life should be read as approximate.
Research material is normally supplied as a freeze-dried powder in sealed vials. In that state the peptide is comparatively robust, but prolonged exposure to warmth, moisture, or light accelerates degradation. Storage at minus twenty degrees Celsius or lower, with desiccant and protection from light, is the commonly described practice. Vials should be allowed to reach room temperature before opening to limit condensation on the powder. Moisture uptake during handling is a recognized source of variability in later measurements.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilized powder | Visual descriptor; not a measure of purity |
| Solubility class | Freely soluble in water | Aqueous dissolution may require gentle mixing |
| Typical storage (powder) | −20 °C or below, desiccated | Protect from light and ambient moisture |
| Typical storage (solution) | 2–8 °C, short term | Freeze aliquots where longer holding is needed |
| Purity assessment | Reversed-phase HPLC, area percent | Values depend on column, gradient, and detection wavelength |
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
Viral vector vaccines use a safe virus to insert pathogen genes in the body to produce specific antigens, such as surface proteins, to stimulate an immune response. Viruses being researched for use as viral vectors include adenovirus, vaccinia virus, and VSV.
== Balanced salt solutions == Alsever's solution Earle's balanced salt solution (EBSS) Gey's balanced salt solution (GBSS) Hanks' balanced salt solution (HBSS) (Dulbecco's) Phosphate buffered saline (PBS) Puck's balanced salt solution Ringer's balanced salt solution (RBSS) Simm's balanced salt solution (SBSS) TRIS-buffered saline (TBS) Tyrode's balanced salt solution (TBSS)
=== Health and social impacts === Extreme weather conditions related to the ENSO cycle correlate with changes in the incidence of epidemic diseases like Influenza pandemic, though studies have come to differing conclusions as to whether they are associated with the El Niño or the La Niña phase of the cycle. El Niño cycles are associated with increased risks of some of the diseases transmitted by mosquitoes, such as malaria, dengue fever, and Rift Valley fever, with the latter having a severe outbreak after extreme rainfall in north-eastern Kenya and southern Somalia during the 1997–98 El Niño. Cycles of malaria in India, Venezuela, Brazil, and Colombia have now been linked to El Niño. Outbreaks of another mosquito-transmitted disease, Australian encephalitis (Murray Valley encephalitis—MVE), occur in temperate south-east Australia after heavy rainfall and flooding, which are associated with La Niña events. ENSO conditions have also been related to Kawasaki disease incidence in Japan and the west coast of the United States, via the linkage to tropospheric winds across the north Pacific Ocean. ENSO may be linked to civil conflicts. Scientists at The Earth Institute of Columbia University, having analyzed data from 1950 to 2004, suggest ENSO may have had a role in 21% of all civil conflicts since 1950, with the risk of annual civil conflict doubling from 3% to 6% in countries affected by ENSO during El Niño years relative to La Niña years.
Ansuvimab, sold under the brand name Ebanga, is a monoclonal antibody medication used for the treatment of Ebolavirus (Zaire ebolavirus) infection. The most common symptoms include fever, tachycardia (fast heart rate), diarrhea, vomiting, hypotension (low blood pressure), tachypnea (fast breathing) and chills; however, these are also common symptoms of Ebolavirus infection. Ansuvimab was approved for medical use in the United States in December 2020. It is on the World Health Organization's List of Essential Medicines. Ansuvimab is composed of a single monoclonal antibody (mAb) and was initially isolated from immortalized B-cells that were obtained from a survivor of the 1995 outbreak of Ebola virus disease in Kikwit, Democratic Republic of the Congo. In work supported by the United States National Institutes of Health and the Defense Advanced Projects Agency, the heavy and light chain sequences of ansuvimab mAb were cloned into Chinese hamster ovary cell lines and initial production runs were produced by Cook Phamica d.b.a. Catalent under contract with Medimmune.
Sources: en.wikipedia.org
93Zr is a radioisotope of zirconium with a half-life of 1.61 million years, decaying through emission of a low-energy beta particle. 73% of decays populate an excited state of niobium-93, which decays with a half-life of 13.9 years (almost entirely by internal conversion, emitting no gamma ray) to the stable ground state of 93Nb, while the remaining 27% of decays directly populate the ground state. It is one of the 7 long-lived fission products. The low specific activity and low energy of its radiation limit the radioactive hazards of this isotope, and its insolubility makes it unlikely to escape a waste repository; all these are shared with palladium-107. Nuclear fission produces it at a fission yield of 6.3% (thermal neutron fission of 235U), one of the most abundant fission products. Nuclear reactors usually contain large amounts of zirconium as fuel rod cladding (see zircalloy), and neutron irradiation of 92Zr also produces some 93Zr, though this is limited by 92Zr's low neutron capture cross section of 0.22 barns. Indeed, one of the primary reasons for using zirconium in fuel rod cladding is its low cross section. 93Zr also has a low neutron capture cross section of 0.7 barns. Most fission zirconium consists of other isotopes; the other isotope with a significant neutron absorption cross section is 91Zr with a cross section of 1.24 barns. 93Zr is a less attractive candidate for disposal by nuclear transmutation than are 99Tc and 129I.
== Side effects == Adverse events include hypoglycemia, pruritus (itch), nasopharyngitis, headache, and upper respiratory tract infection. It may also cause joint pain that can be severe and disabling. Like other DDP-4 inhibitors, alogliptin is weight-neutral. A 2014 letter to the editor claimed alogliptin is not associated with increased risk of cardiovascular events. In April 2016, the U.S. Food and Drug Administration (FDA) added a warning about increased risk of heart failure.
Supplement products are, or contain, vitamins, nutritionally essential minerals, amino acids, essential fatty acids, non-nutrient substances extracted from plants, animals, fungi or bacteria, and in the instance of probiotics, live microorganisms. Dietary supplement ingredients may also be synthetic copies of naturally occurring substances (for example: melatonin). All products with these ingredients are required to be labeled as dietary supplements in the United States. Like foods, but unlike drugs, no government approval is required to make or sell dietary supplements; instead, the manufacturer itself confirms the safety of dietary supplements. Rather than requiring risk–benefit analysis to prove that the product can be sold like a drug, such assessment is only used by the FDA to decide that a dietary supplement is unsafe and should be removed from market.
Sources: en.wikipedia.org
Cool, dark, and dry conditions are standard, with storage at minus twenty degrees Celsius or below. Desiccant and sealed vials limit moisture uptake. Repeated warming and cooling of the container is generally avoided.
There is no single agreed limit, and laboratory practice varies widely. Refrigeration slows degradation, and freezing aliquots is often described for longer holding. Any visible cloudiness or precipitate indicates the solution should be discarded.
Mass spectrometry provides the most direct confirmation through molecular mass. Reversed-phase chromatography supports purity assessment, and peptide mapping or amino acid analysis can corroborate sequence. No single method establishes both purity and identity on its own.
A maleimide moiety reacts with the thiol of cysteine-34, forming a covalent bond. The reaction occurs in circulation without enzymatic catalysis.